THE SEATTLE II TRIAL

A Prospective, Single-Arm, Multicentre Trial of Ultrasound-Facilitated, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmonary Embolism

G. Piazza MD, MS et al, Presented, American College of Cardiology (ACC) meeting, Washington, DC, March 2014

Patients

Acute Massive and Submassive PE with RV/LV ratio ≥ 0.9
(n = 150; 22 centers)

Objectives

Evaluate ultrasound-facilitated, catheter-directed low-dose fibrinolysis:

- **Efficacy** – as measured by reduction in RV/LV ratio
- **Safety** – as measured by major bleeding within 72 hours

Method

- **Ultrasound-facilitated fibrinolysis using EKOS®**
  - If unilateral PE
    - tPA 1 mg/hr using one device for 24 hours
  - If bilateral PE
    - tPA 1 mg/hr per device (using two simultaneously) for 12 hours
- **Follow up at 48 +/- 6 hours**
  - CT measurement of RV/LV ratio
  - Echocardiogram to estimate PA systolic pressure
**CONCLUSION**

Ultrasound-facilitated, catheter-directed, low-dose fibrinolysis for acute PE improves RV function and decreases pulmonary hypertension and angiographic obstruction. By minimizing the risk of intracranial bleed, it represents a potential “game-changer” in the treatment of high-risk PE patients.